PDF herunterladen
CC BY 4.0 · TH Open 2021; 05(04): e470-e478
DOI: 10.1055/s-0041-1736289
Original Article

Evaluation of Frequency, Clinical Correlation, and Antibodies Confirmation Profile in Patients with Suspected Antiphospholipid Syndrome

Filipe F. Martins 
1   Department of Immunohemotherapy, Tâmega e Sousa Hospital Center, Penafiel, Portugal
,
Teresa M. L. Campos
1   Department of Immunohemotherapy, Tâmega e Sousa Hospital Center, Penafiel, Portugal
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial and venous thrombotic manifestations and/or pregnancy-related complications in patients with persistent antiphospholipid (aPL) antibodies. The introduction of Sapporo's classification criteria allowed uniformity in the classification of this pathology, representing a considerable advance in its diagnosis. However, currently some doubts about the application of these criteria still persist. The aim of this study was to contribute to the better understanding of APS by the assessment of aPL prevalence, the association between clinical and laboratory tests, and evaluation of the aPL confirmatory profile.

In this study, 1,179 samples from patients with suspected APS of both genders, without age restrictions, who were advised to test for complete aPL's profile were analyzed. The samples were tested for lupus anticoagulant (LAC), anticardiolipin immunoglobulin (Ig) G/IgM and anti-β-2-glycoprotein I IgG/IgM antibodies. Patient samples with isolated test requests for analysis and samples from patients under the influence of anticoagulants or in an infectious process were excluded.

The overall positivity found was 17.9% and the most frequent aPL was LAC. The antibodies were determined in isolation and in association. The prevalence of triple positivity was 0.8% and double positivity was 1.8%. Positivity was higher in inpatient/emergency services compared with outpatient services. There was a higher positivity in individuals over 41 years, males, patients with systemic lupus erythematosus, kidney complications, and deep vein thrombosis/thrombophlebitis. The positivity confirmation with second sample was 39.5% and the confirmation profile shows that 50.6% of samples confirmed with same positivity profile; 17.3% with a different profile and regarding to these, 2.5% of the samples confirmed positivity with a different antibody from the previously detected.

This study suggests that the aPL's positivity tends to increase with age, showing that the aPL's testing should be avoided during an acute event and reinforces the need for complete aPL laboratory profile in the second sample and subsequent determinations.

Keywords

antiphospholipid syndrome - antiphospholipid antibodies - anticardiolipin - anti-β2-glycoprotein I - lupus anticoagulant - thrombosis


Publikationsverlauf

Eingereicht: 10. Mai 2021

Angenommen: 11. August 2021

Artikel online veröffentlicht:
19. Oktober 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003; 168 (13) 1675-1682
    PubMedGoogle Scholar
  • 2 Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157 (01) 47-58
    CrossrefPubMedGoogle Scholar
  • 3 Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 2014; 48-49: 20-25
    CrossrefPubMedGoogle Scholar
  • 4 Cervera R, Piette JC, Font J. et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46 (04) 1019-1027
    CrossrefPubMedGoogle Scholar
  • 5 Asherson RA, Cervera R. Pulmonary hypertension, antiphospholipid antibodies, and syndromes. Clin Rev Allergy Immunol 2007; 32 (02) 153-158
    CrossrefPubMedGoogle Scholar
  • 6 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
    CrossrefPubMedGoogle Scholar
  • 7 Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. Semin Thromb Hemost 2012; 38 (04) 333-338
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Cervera R, Serrano R, Pons-Estel GJ. et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74 (06) 1011-1018
    CrossrefPubMedGoogle Scholar
  • 9 Devreese K, Hoylaerts MF. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem 2010; 56 (06) 930-940
    CrossrefPubMedGoogle Scholar
  • 10 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (07) 1309-1311
    CrossrefPubMedGoogle Scholar
  • 11 Duarte-Garcia A, Pham MM, Crowson CS. et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheum 2019; 71 (09) 1545-1552
    CrossrefPubMedGoogle Scholar
  • 12 Sangle NA, Smock KJ. Antiphospholipid antibody syndrome. Arch Pathol Lab Med 2011; 135 (09) 1092-1096
    CrossrefPubMedGoogle Scholar
  • 13 Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev 2017; 31 (06) 406-417
    CrossrefPubMedGoogle Scholar
  • 14 Raby A, Moffat K, Crowther M. Anticardiolipin antibody and anti-beta 2 glycoprotein I antibody assays. Methods Mol Biol 2013; 992: 387-405
    CrossrefPubMedGoogle Scholar
  • 15 Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost 2016; 14 (08) 1530-1548
    CrossrefPubMedGoogle Scholar
  • 16 Al-Balushi MS, Hasson SS, Said EA. et al. Fluctuation in the levels of immunoglobulin M and immunoglobulin G antibodies for cardiolipin and β2-glycoprotein among healthy pregnant women. Sultan Qaboos Univ Med J 2014; 14: 478-485
    PubMedGoogle Scholar
  • 17 Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV. et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2007; 16 (10) 810-816
    CrossrefPubMedGoogle Scholar
  • 18 Les I, Parraza N, Anaut P. et al. Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study. Rheumatol Int 2018; 38 (02) 229-238
    CrossrefPubMedGoogle Scholar
  • 19 Stojanovich L, Markovic O, Marisavljevic D, Elezovic I, Ilijevski N, Stanisavljevic N. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study. Lupus 2012; 21 (03) 338-345
    CrossrefPubMedGoogle Scholar
  • 20 Fujieda Y, Atsumi T, Amengual O. et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 2012; 21 (14) 1506-1514
    CrossrefPubMedGoogle Scholar
  • 21 Gómez-Puerta JA, Espinosa G, Cervera R. Antiphospholipid antibodies: from general concepts to its relation with malignancies. Antibodies (Basel) 2016; 5 (03) E18
    CrossrefPubMedGoogle Scholar
  • 22 Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus 2014; 23 (14) 1468-1476
    CrossrefPubMedGoogle Scholar
  • 23 Pengo V, Ruffatti A, Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (02) 237-242
    CrossrefPubMedGoogle Scholar
  • 24 Pengo V, Testa S, Martinelli I. et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 2015; 135 (01) 46-49
    CrossrefPubMedGoogle Scholar
  • 25 Ruffatti A, Tonello M, Del Ross T. et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96 (03) 337-341
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 26 Yelnik CM, Urbanski G, Drumez E. et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus 2017; 26 (02) 163-169
    CrossrefPubMedGoogle Scholar
  • 27 Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A. Italian Federation of anticoagulation clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performange of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res 2007; 120: 127-133
    CrossrefPubMedGoogle Scholar
  • 28 Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol 2012; 87 (Suppl. 01) S75-S81
    CrossrefPubMedGoogle Scholar
  • 29 Out HJ, de Groot PG, Hasselaar P, dan Vliet M, Derksen RH. Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 1989; 48 (12) 1023-1028
    CrossrefPubMedGoogle Scholar
  • 30 Devreese KMJ, Ortel TL, Pengo V, de Laat B. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (04) 809-813
    CrossrefPubMedGoogle Scholar
  • 31 Asherson RA, Khamashta MA, Ordi-Ros J. et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68 (06) 366-374
    Google Scholar
  • 32 Font J, López-Soto A, Cervera R. et al. The ‘primary’ antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 1991; 9 (01) 69-75
    CrossrefPubMedGoogle Scholar
  • 33 Jara LJ, Medina G, Vera-Lastra O, Barile L. The impact of gender on clinical manifestations of primary antiphospholipid syndrome. Lupus 2005; 14 (08) 607-612
    CrossrefPubMedGoogle Scholar
  • 34 Manukyan D, Rossmann H, Schulz A. et al. Distribution of antiphospholipid antibodies in a large population-based German cohort. Clin Chem Lab Med 2016; 54 (10) 1663-1670
    CrossrefPubMedGoogle Scholar
  • 35 Hwang JJ, Shin SH, Kim YJ. et al. Epidemiology of antiphospholipid syndrome in Korea: a nationwide population-based study. J Korean Med Sci 2020; 35 (05) e35
    CrossrefPubMedGoogle Scholar
  • 36 Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus–a meta-analysis. Lupus 1997; 6 (05) 467-473
    CrossrefPubMedGoogle Scholar
  • 37 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (05) 1827-1832
    CrossrefPubMedGoogle Scholar
  • 38 Male C, Foulon D, Hoogendoorn H. et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106 (13) 4152-4158
    CrossrefPubMedGoogle Scholar
  • 39 Medina G, Briones-García E, Cruz-Domínguez MP, Flórez-Durante OI, Jara LJ. Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence. Autoimmun Rev 2017; 16 (04) 352-354
    CrossrefPubMedGoogle Scholar
  • 40 Riancho-Zarrabeitia L, Daroca G, Muñoz P, López-Hoyos M, Haya A, Martínez-Taboada VM. Serological evolution in women with positive antiphospholipid antibodies. Semin Arthritis Rheum 2017; 47 (03) 397-402
    CrossrefPubMedGoogle Scholar
  • 41 Erkan D, Derksen WJ, Kaplan V. et al. Real world experience with antiphospholipid antibody tests: how stable are results over time?. Ann Rheum Dis 2005; 64 (09) 1321-1325
    CrossrefPubMedGoogle Scholar
  • 42 Mizumoto H, Maihara T, Hiejima E. et al. Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature. Eur J Pediatr 2006; 165 (07) 484-488
    CrossrefPubMedGoogle Scholar
  • 43 Nakayama T, Akahoshi M, Irino K. et al. Transient antiphospholipid syndrome associated with primary cytomegalovirus infection: a case report and literature review. Case Rep Rheumatol 2014; 2014: 271548
    PubMedGoogle Scholar
  • 44 Delgado P, Robles Á, Martínez López JA. et al. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 3: childbirth. Puerperium. Breastfeeding contraception. Newborn. Reumatol Clin (Engl Ed) 2021; 17 (04) 183-186
    CrossrefPubMedGoogle Scholar
  • 45 de Bandt M, Benali K, Guillevin L. et al. Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. J Rheumatol 1999; 26 (01) 91-96
    PubMedGoogle Scholar